Sepragen and Neugenesis sign collaboration agreement

The collaboration would involve Neugenesis growing its Neurospora expression system in Sepragen’s solid phase bioreactor system. Neurospora expression systems enable faster production of recombinant proteins than mammalian cells and Sepragen’s bioreactor enables multi-fold growth of a variety of cells without limitations of oxygen inhibition.

The project is funded in part by a Defense Advance Research Projects Agency contract to Neugenesis under the Accelerated Manufacturing Process project to develop a high throughput platform for low cost development of vaccines for pandemic flu.

Vinit Saxena, CEO of Sepragen, said: “We believe that our platform can provide the means for Neurospora to grow rapidly without limitation of oxygen depletion and can, thus, form the basis for high throughput production of antibodies, based on this expression system.”